The US Food and Drug Administration (FDA) has approved a new shot to prevent HIV, offering a long-acting alternative to daily ...

The approval of Lenacapavir – a twice-yearly antiviral HIV-preventing medication marketed under the brand name Yeztugo – by the US Food and Drug Administration (FDA), has been welcomed by the global ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

In a major step forward for HIV prevention, the FDA has approved lenacapavir—branded as Yeztugo the first HIV prevention shot that only needs to be taken twice a year.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

On Wednesday, the Food and Drug Administration approved a highly effective, injectable drug to help prevent the transmission ...

The U.S. Food and Drug Administration approved an HIV prevention medication that has been proven highly effective in clinical ...